Articles about 'Cystic Fibrosis Trust'

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown. It is not clear, however, whether these mutated viruses pose an increased risk to patients or are able to evade the vaccine.

A major new institute opens today, bringing together the largest concentration of scientists and clinicians in heart and lung medicine in Europe.

Scientists have been able to track how a multi-drug resistant organism is able to evolve and spread widely among cystic fibrosis patients – showing that it can evolve rapidly within an individual during chronic infection.

The University of Cambridge and Royal Papworth Hospital held an official ground-breaking ceremony at the new Heart and Lung Research Institute (HLRI) in Cambridge earlier today. The Institute is based on the Cambridge Biomedical Campus and will create the largest cardiothoracic centre for research, education, industry collaboration, and clinical care in Europe.